Biological
SCTV01C vaccine clinical trials
Also written SCTV01E and SCTV01C.
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2022 (10)
| Year | Studies |
|---|---|
| 2021 | 3 |
| 2022 | 10 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 15
Who runs them
Industry 15 · Other 0
Studies
Open first, then newest update. How each study uses SCTV01C vaccine is read from its arms, and is right about nine times in ten.
Testing it · 15
- A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 YearsActive, not recruitingPhase 3Sinocelltech Ltd.NCT05308576Written as SCTV01E
- A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 YearsWithdrawnPhase 2Sinocelltech Ltd.NCT05308602Written as SCTV01C
- A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 VaccineWithdrawnPhase 2Sinocelltech Ltd.NCT05239975Written as SCTV01C
- The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated AdultsCompletedPhase 1/2Sinocelltech Ltd.NCT05148091Written as SCTV01C
- A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 VaccineCompletedPhase 2Sinocelltech Ltd.NCT05652543Written as SCTV01E
- A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster VaccinesStatus unknownPhase 3Sinocelltech Ltd.NCT05323461Written as SCTV01C
- A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy PeopleStatus unknownPhase 3Sinocelltech Ltd.NCT05683561Written as SCTV01E
- A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 YearsStatus unknownPhase 2Sinocelltech Ltd.NCT05522829Written as SCTV01E-1 on D0
- A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 YearsStatus unknownPhase 2Sinocelltech Ltd.NCT05345873Written as SCTV01E
- A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 YearsStatus unknownPhase 2Sinocelltech Ltd.NCT05329051Written as SCTV01E
- A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 VaccineStatus unknownPhase 2Sinocelltech Ltd.NCT05239806Written as SCTV01C
- A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 VaccineStatus unknownPhase 2Sinocelltech Ltd.NCT05238441Written as SCTV01E
- A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 VaccineStatus unknownPhase 2Sinocelltech Ltd.NCT05238454Written as SCTV01C
- The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.Status unknownPhase 1/2Sinocelltech Ltd.NCT05043285Written as SCTV01C
- The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.Status unknownPhase 1/2Sinocelltech Ltd.NCT05043311Written as SCTV01C
As the comparator · 1 — what is tested is compared with SCTV01C vaccine
Codes
What other systems call SCTV01C vaccine · ClinicalTrials.gg INT001711
- MeSH (NLM) C000719256SCTV01C vaccineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719256 | SCTV01C vaccine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.